Advantages and disadvantages of topical antifungal agents;Ventajas y desventajas de los antifúngicos de uso tópico

Revista Espanola de Quimioterapia

Volumn 14, Issue 3, 2001, Pages 232-237

  Maestre Vera, J R ^a   Alou Cervera, L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUTRIMAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; NYSTATIN; SERTACONAZOLE; TERBINAFINE; VORICONAZOLE;

ASPERGILLUS; CANDIDA ALBICANS; HUMAN; MYCOSIS; PITYROSPORUM; REVIEW; STREPTOMYCES; TINEA CAPITIS; TINEA CORPORIS; TINEA PEDIS;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CANDIDIASIS; DERMATOMYCOSES; HUMANS;

EID: 0035204423     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Mémoire sur une végetátion qui constitue la vraie teigne
2. Sur un nouveau crytogame qui se développe dans la racine des poils de la barbae et constitue une espéce de mentagre contagieuse
3. De la structure anatomico-pathologique du muguet (lettre à M. Gruby)
4. Muco-cutaneous candidiasis: Historical aspects
5. Micología. Importancia de los hongos
6. Impact of the changing epidemiology of fungal infections in the 1990s
7. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
8. Candidemia in immunocompromised patients
9. Candida and Aspergillus infections in immunocompromised patients: An overview
10. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
11. The Medical Micological keberg
12. Importancia de las dermatofitosis en patología humana y animal
13. Dermatofitos o tiñias
14. Clinical and economic factors in the treatment of onychomycosis
15. The changing epidemiology and emerging patterns of dermatophyte species
16. Antitrichophyton activity of naphthiomates
17. Toinaftate
18. Use of antibiotics. Antifungals
19. Experimental ringworm in guinea pigs. Oral treatment with griseofulvin
20. Oral treatment of ringworm with griseofulvin
21. Griseofulvin
22. The imidazoles
23. Imidazoles as medically important antifungal agents: An overview
24. Clotrimazole
25. Le spectre antifungique in vitro e in vivo da kétoconazole
26. The synthesis and antifungal activity of ketoconazole, a new potent orally active broadspectrum antifungal agent
27. Ketoconazole: A major innovation for treatment of fungal disease
28. Flucytosine
29. Mode of action of 5-fluorocytosine
30. Two antifungal agents produced by a soil actinomycete
31. A pharmacologic guide to the clinical use of amphotericin
32. New antifungals agents
33. Fluconazole, a new antifungal agent
34. Azoles, allylamines and drug metabolism
35. Recent developments in antifungal therapy
36. Itraconazole
37. In vitro activity of naftifine, a new antifungal agent
38. In vivo antimycotic activity of naftifine
39. Synthesis and structure-activity correlations within allylamine antimicotics
40. Antifungal activity of the allylamine derivate terbinafine in vitro
41. The early development of allylamine antimycotic
42. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
43. Ciclopirox: A new topical pyrodonium antimicotic agent. A double-blind study in superficial dermatomycoses
44. Ciclopirox olamina 1% cream. A preliminary review of its antimicrobial activity and therapeutic use
45. Amorolfine
46. Antifungal agents: An overview
47. An overview of topical antifungal therapy in dermatomycoses. A North American perspective
48. Clinical evaluation of bifonazole for moccasin-type tinea pedis
49. Treatment and prophylaxis of tinea infections
50. Itraconazole in the treatment of tinea capitis
51. Fluconazole for the treatment of tinea capitis in children
52. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories
53. Management of neonatal candidiasis. Neonatal study group
54. Treatment of oropharyngeal candidiasis in immunocompetent infants: A randomized multicenter study of miconazol gel vs. nystatin suspension. The Antifungal Study Group
55. Pityrosporum infections
56. Treatment of Pityrosporum infections
57. Treatment of Pityriasis versicolor with a shampoo containing 1% bifonazole in children
58. Treatment of seborrhoeic dermatitis with bifonazole
59. Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo controlled trial
60. Double-blind randomized dose-finding study in acute vulvovaginal candidosis. Comparison of flutrimazole site-release cream (1, 2 and 4 %) with placebo site-release vaginal cream
61. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis
62. In vitro susceptibility of seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine
63. The mechanism of action of terbinafine
64. Systematic review of topical treatments for fungal infections of the skin and nails of the feet
65. Short-term therapy of tinea cruris/corporis with topical terbinafine
66. Short duration therapy with terbinafine 1% cream in dermatophyte skin infections
67. Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine
68. Terbinafine: Efficacy and safety in the treatment of dermatophytosis
69. The efficacy of a topical application of terbinafine 1% solution in subjects with Pityriasis versicolor
70. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails
71. Pharmacokinetic of terbinafine in the nail
72. Butenafine
73. Butenafine hydrochloride for the treatment of interdigital tinea pedis
74. Treatment of interdigital tinea pedis with 4-week once daily regimen of butenafine hydrochloride 1% cream
75. Ciclopirox nail lacquer and pediatric practice
76. Ciclopirox nail lacquer solution 8% in the 21st century
77. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: Comparative efficacy and tolerability of once and twice weekly use
78. The preparation and properties of crystalline fungicidin (nystatin)
79. Chemistry and biology of the polyene macrolide antibiotics
80. Molecular mechanisms of drug resistance in fungi
81. Candidosis
82. Profilaxis contra Candida spp. con suspension de nistatina en pacientes seropositivos al virus de la inmunodeficiencia humana
83. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients
84. Prophylaxis with nystatin pastillas for HIV-associated oral candidiasis
85. The treatment of thrush with gentian violet
86. The discovery and development of amphotericin B
87. Amphotericin B: Current understanding of mechanisms of action
88. Amphotericin B oral suspension in treatment of thrush
89. Topical amphotericin B application in severe bronchial aspergillosis after lung transplantation: Report of experiences in 3 cases
90. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region
91. Therapy of onychomycosis